高级检索

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

人体微生物组特征与肺癌相关性研究进展

陈佳丽 李士杰 卓明磊 张娜 金美玲 郭金鹏 王长军 陈勇

陈佳丽, 李士杰, 卓明磊, 张娜, 金美玲, 郭金鹏, 王长军, 陈勇. 人体微生物组特征与肺癌相关性研究进展[J]. 中国公共卫生, 2023, 39(2): 177-180. doi: 10.11847/zgggws1138835
引用本文: 陈佳丽, 李士杰, 卓明磊, 张娜, 金美玲, 郭金鹏, 王长军, 陈勇. 人体微生物组特征与肺癌相关性研究进展[J]. 中国公共卫生, 2023, 39(2): 177-180. doi: 10.11847/zgggws1138835
CHEN Jia-li, LI Shi-jie, ZHUO Ming-lei, . Advance in researches on relationship between human microbiome and lung cancer: a review[J]. Chinese Journal of Public Health, 2023, 39(2): 177-180. doi: 10.11847/zgggws1138835
Citation: CHEN Jia-li, LI Shi-jie, ZHUO Ming-lei, . Advance in researches on relationship between human microbiome and lung cancer: a review[J]. Chinese Journal of Public Health, 2023, 39(2): 177-180. doi: 10.11847/zgggws1138835

人体微生物组特征与肺癌相关性研究进展

doi: 10.11847/zgggws1138835
基金项目: 北京市科技新星项目(Z181100006218107)
详细信息
    作者简介:

    陈佳丽(1995 – ),女,四川眉山人,硕士在读,研究方向:微生物组学

    通信作者:

    王长军,E-mail:science2008@hotmail.com

    陈勇,E-mail:chenyonger@126.com

  • 中图分类号: R 734.2

Advance in researches on relationship between human microbiome and lung cancer: a review

  • 摘要: 中国肺癌的发病人数和死亡人数居高不下,是最常见且预后较差的恶性肿瘤之一。近年来,随着测序技术的不断发展,有关微生物组与肺癌之间关联的研究增多,其主要目的是探索微生物组与肺癌之间的潜在关联和寻找早期肺癌的标志物诊断,以期为临床诊断及治疗提供参考依据。有研究提示肺癌患者与健康人群各部位的微生物组有明显差异,同时,也有研究提示其他呼吸系统疾病带来的微生物组变化也会影响肺癌的发生发展。本文对微生物组与肺癌之间的关系进行综述,总结了目前研究中存在的不足,并对今后的研究作出了展望。
  • 图  1  健康和肺癌人群不同部位主要菌群种类差异

    注:左边为健康人群口腔、肺部及肠道主要菌群种类;右边为肺癌患者口腔、肺部及肠道主要菌群种类。

  • [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660
    [2] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1 – 13.
    [3] Schwartz AG, Cote ML. Epidemiology of lung cancer[J]. Advances in Experimental Medicine and Biology, 2016, 893: 21 – 41.
    [4] Zhao LP. The tale of our other genome[J]. Nature, 2010, 465(7300): 879 – 880. doi: 10.1038/465879a
    [5] Mao QX, Jiang F, Yin R, et al. Interplay between the lung microbiome and lung cancer[J]. Cancer Letters, 2018, 415: 40 – 48. doi: 10.1016/j.canlet.2017.11.036
    [6] Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal[J]. Microbiome, 2015, 3: 31. doi: 10.1186/s40168-015-0094-5
    [7] Lemon KP, Klepac-Ceraj V, Schiffer HK, et al. Comparative analyses of the bacterial microbiota of the human nostril and oropharynx[J]. mBio, 2010, 1(3): e00129 – 10.
    [8] 张鑫. 肺癌患者呼吸道菌群结构及代谢组特征分析与比较研究[D]. 上海: 中国人民解放军海军军医大学, 2019: 83 – 86.
    [9] Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis[J]. The Lancet Respiratory Medicine, 2014, 2(3): 238 – 246. doi: 10.1016/S2213-2600(14)70028-1
    [10] Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals[J]. mBio, 2015, 6(2): e00037.
    [11] 杨晓晖, 董航明, 蔡绍曦. 人体微生物组与肺癌[J]. 中国呼吸与危重监护杂志, 2017, 16(4): 417 – 420. doi: 10.7507/1671-6205.201701012
    [12] Kovaleva O, Podlesnaya P, Rashidova M, et al. Lung microbiome differentially impacts survival of patients with non-small cell lung cancer depending on tumor stroma phenotype[J]. Biomedicines, 2020, 8(9): 349. doi: 10.3390/biomedicines8090349
    [13] Dong H, Tan Q, Xu YY, et al. Convergent alteration of lung tissue microbiota and tumor cells in lung cancer[J]. iScience, 2022, 25(1): 103638. doi: 10.1016/j.isci.2021.103638
    [14] Jang HJ, Choi JY, Kim K, et al. Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer[J]. Respiratory Research, 2021, 22(1): 322. doi: 10.1186/s12931-021-01919-1
    [15] Liu HX, Tao LL, Zhang J, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects[J]. International Journal of Cancer, 2018, 142(4): 769 – 778. doi: 10.1002/ijc.31098
    [16] Huang DH, Su XF, Yuan M, et al. The characterization of lung microbiome in lung cancer patients with different clinico-pathology[J]. America Journal of Cancer Research, 2019, 9(9): 2047 – 2063.
    [17] Meyer MS, Joshipura K, Giovannucci E, et al. A review of the relationship between tooth loss, periodontal disease, and cancer[J]. Cancer Causes and Control, 2008, 19(9): 895 – 907. doi: 10.1007/s10552-008-9163-4
    [18] Bingula R, Filaire E, Molnar I, et al. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial[J]. Respiratory Research, 2020, 21(1): 129. doi: 10.1186/s12931-020-01392-2
    [19] Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life[J]. Tissue Barriers, 2017, 5(4): e1373208. doi: 10.1080/21688370.2017.1373208
    [20] 滕俊, 赵艳芬, 姜云宁, 等. 肠道菌群与肺癌的相关性[J]. 中国肺癌杂志, 2020, 23(10): 909 – 915. doi: 10.3779/j.issn.1009-3419.2020.101.39
    [21] Zhang WQ, Zhao SK, Luo JW, et al. Alterations of fecal bacterial communities in patients with lung cancer[J]. America Journal of Translational Research, 2018, 10(10): 3171 – 3185.
    [22] Bingula R, Filaire M, Radosevic-Robin N, et al. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma[J]. Medicine, 2018, 97(50): e13676. doi: 10.1097/MD.0000000000013676
    [23] Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis[J]. PLoS One, 2011, 6(3): e17479. doi: 10.1371/journal.pone.0017479
    [24] Schreiber H, Nettesheim P, Lijinsky W, et al. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infec-tion[J]. Journal of the National Cancer Institute, 1972, 49(4): 1107 – 1114.
    [25] Qiao D, Wang ZY, Lu YH, et al. A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients[J]. America Journal of Cancer Research, 2015, 5(1): 423 – 432.
    [26] 章树佳. 慢性阻塞性肺病对肺癌患者肺部菌群构成影响的相关性研究[D]. 广州: 南方医科大学, 2020: 52 – 54.
    [27] Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention[J]. COPD, 2008, 5(4): 235 – 256. doi: 10.1080/15412550802237531
    [28] Jin CC, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells[J]. Cell, 2019, 176(5): 998 – 1013.e16. doi: 10.1016/j.cell.2018.12.040
    [29] Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy[J]. Nature Medicine, 2019, 25(3): 377 – 388. doi: 10.1038/s41591-019-0377-7
    [30] Cheng C, Wang ZF, Wang JQ, et al. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer[J]. Translational Lung Cancer Research, 2020, 9(3): 693 – 704. doi: 10.21037/tlcr-19-590
    [31] Yan XM, Yang MX, Liu J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer[J]. America Journal of Cancer Research, 2015, 5(10): 3111 – 3122.
    [32] Zheng YJ, Fang ZY, Xue Y, et al. Specific gut microbiome signature predicts the early-stage lung cancer[J]. Gut Microbes, 2020, 11(4): 1030 – 1042. doi: 10.1080/19490976.2020.1737487
    [33] Ma Y, Qiu MT, Wang SD, et al. Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules[J]. Translational Oncology, 2021, 14(6): 101050. doi: 10.1016/j.tranon.2021.101050
    [34] Lee SH, Sung JY, Yong D, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions[J]. Lung Cancer, 2016, 102: 89 – 95. doi: 10.1016/j.lungcan.2016.10.016
    [35] Jin YP, Dong H, Xia LL, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. Journal of Thoracic Oncology, 2019, 14(8): 1378 – 1389. doi: 10.1016/j.jtho.2019.04.007
    [36] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97 – 103. doi: 10.1126/science.aan4236
    [37] He DQ, Li X, An R, et al. Response to PD-1-based immunotherapy for non-small cell lung cancer altered by gut microbiota[J]. Oncology and Therapy, 2021, 9(2): 647 – 657. doi: 10.1007/s40487-021-00171-3
  • 加载中
图(1)
计量
  • 文章访问数:  320
  • HTML全文浏览量:  153
  • PDF下载量:  37
  • 被引次数: 0
出版历程
  • 接收日期:  2022-04-14
  • 网络出版日期:  2022-12-26
  • 刊出日期:  2023-02-10

目录

    /

    返回文章
    返回